An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Psoriasis

Interventions

DRUG

KHK4827

140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)

Trial Locations (1)

For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Chiyoda-ku

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT01782937 - An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis | Biotech Hunter | Biotech Hunter